60 Degrees Pharma Eyes Commercialization Amid Going-Concern Warning and July Capital Raise

Quick take - 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP)

What's happening inside the company
- Management is pushing commercialization of Arakoda and running multiple R&D programs (babesiosis, packaging validation, clinical supply contracts).
- Company completed multiple small registered direct offerings in Jan/Feb 2025 and a larger July 2025 registered direct offering that closed for ~ $4.46M net proceeds on July 16, 2025.
- Management warns of a going-concern (substantial doubt) and disclosed material weaknesses in internal controls (insufficient accounting headcount, segregation of duties, and limited in-house technical accounting expertise).
- Capital raises are the primary funding source; July 2025 proceeds extend runway to ~March 31, 2026 per MD&A, but additional capital may be required thereafter.

Key facts & figures (as reported)
- Cash and cash equivalents (June 30, 2025): $1,966,930.
- Total assets (June 30, 2025): $4,181,938. Total liabilities: $1,836,234. Shareholders' equity: $2,345,704.
- Common stock issued & outstanding (June 30, 2025): 1,472,891 shares (note: registrant reported 4,104,469 shares issued and outstanding as of August 13, 2025).
- Series A Preferred outstanding: 76,480 shares; cumulative dividends accrued on Series A (as of June 30, 2025): $948,878 (dividends accrued in the period: $126,705 three months / $244,863 six months).
- Derivative liabilities (Level 3 contingent milestone to Knight): $776,172 (June 30, 2025), up from $640,830 (Dec 31, 2024); marked-to-market swings hit the P&L (loss of $140,447 in the quarter).
- Customer concentration: significant customers represent ~94% of accounts receivable and ~99% of product revenue in the quarter-very concentrated.

Income statement - headline numbers
- Product revenues (Q2 2025): $100,932; Product revenues (6 months 2025): $264,484.
- Research revenues (Q2 2025): $206,939 (vs $728 prior year quarter) - driven by USAMMDA and clinical supply contracts.
- Net revenue (Q2 2025): $257,820 (6 months: $440,831).
- Gross profit (Q2 2025): $50,881; gross margin improved to 50.41% (Q2 2024: 28.33%).
- Research & development expense (Q2 2025): $249,884 (Q2 2024: $3,095,326) - prior-year included a large non-cash stock charge related to University of Kentucky.
- General & administrative (Q2 2025): $1,612,764 (up ~43% vs Q2 2024); sales/marketing, promotions and investor outreach are major drivers.
- Loss from operations (Q2 2025): $(1,604,828). Net loss attributable to company (Q2 2025): $(1,733,726).
- Net loss per common share (basic & diluted): Q2 2025 = $(1.25); six months 2025 = $(2.79). Weighted average common shares (basic & diluted) Q2 2025 = 1,472,891.

Cash flow & financing
- Net cash used in operating activities (six months ended June 30, 2025): $(3,047,494).
- Net cash from financing in H1 2025: ~$1.7M (Jan + Feb offerings net proceeds ~ $804K + $909K).
- Subsequent July 2025 offering net proceeds: ~ $4.46M (closed July 16, 2025) - management projects runway to March 31, 2026 assuming no other raises.

Positives on the income statement
- Gross margin recovery: gross margin rose materially (Q2 2025 50.41% vs Q2 2024 28.33%), driven by lower rebates/mix and lower per-unit cost for new packaging.
- Research revenues scaled up sharply (USAMMDA and University of Kentucky contracts) and meaningfully supplement product sales.
- Company is successfully raising capital via public offerings and pre-funded warrant structures to fund operations.

Negatives on the income statement
- Large recurring net losses and high operating expenses: G&A rising sharply (investor outreach, promo) while company still burning cash (~$3.05M operating burn in H1 2025).
- R&D remains significant (though down vs prior-year non-cash spike) and ongoing trials will consume cash.
- Volatile non-operating items - derivative liability remeasurements are material and swing P&L (quarterly mark-to-market loss of $140K; six-month change = $(135,342)).
- Severe customer concentration on revenue exposes the company to distributor / payer risk; loss or underperformance of a major customer would sharply impact sales.
- Series A preferred cumulative dividend accruals and contingent milestone obligations (potential $10M payment on sale/Change of Control to Knight) reduce flexibility and create downside dilution/claims on future proceeds.

Operational & governance risks to watch
- Going concern: auditors and management disclose substantial doubt about ability to continue without additional financing.
- Internal control weaknesses: material weaknesses noted (staffing, segregation of duties, technical accounting).
- Supply chain concentration: single-source API/vendor history and distributor exclusivity in some geographies - operational risk for product availability.
- Warrants & potential dilution: multiple warrant tranches outstanding (including July 2025 issuance) could materially dilute common holders upon exercise.

Bottom line - concise assessment
- 60 Degrees Pharmaceuticals is moving on commercialization and R&D (Arakoda packaging changes, babesiosis development) and has secured capital raises that temporarily extend runway.
- Financial health remains fragile: persistent operating losses, heavy operating cash burn, material control weaknesses, concentrated customers, a growing Level‑3 derivative liability and preferred stock obligations create meaningful execution and financing risk.
- Investors should watch cash runway (post-July proceeds), pace of G&A and R&D spend, resolution of internal control issues, revenue diversification beyond a few distributors, and the contingent $10M Knight milestone exposure.

If you want, I can convert these points into a one-page investor memo or prepare a short risks-and-opportunities slide for management/board review.